Clinical Trial Update: A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation [Phase 3]

View source ↗

Summary

Phase 3 study evaluating AXS-05 for agitation in Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Agitation
• Alzheimer Disease

Drugs mentioned

• AXS-05 (dextromethorphan-quinidine)

Snippet

Sponsor: Axsome Therapeutics, Inc. | Conditions: Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 3 | Status: COMPLETED